Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced new data of blarcamesine in a new Parkinson's model of combined alpha-synuclein pathology and noradrenergic degeneration. Significant treatment effects of blarcamesine were detected using both a test of impaired motor function and a biomarker of dopaminergic nerve fiber density, indicating fiber regrowth in striatum after 6 weeks of blarcamesine treatment. Results were presented at the AD/PD™ 2026 Conference.

The model addresses both alpha-synuclein accumulation (protein buildup) and noradrenergic degeneration, a combination of lesions that mimics key aspects of Parkinson's disease pathology. The study, presented at the AD/PD™ 2026 Conference, examines whether modulating these interconnected disease pathways with blarcamesine can actively counteract and reverse Parkinson's disease progression.